Dapsone Induced Methemoglobinemia Study (DIMS)
OBJECTIVES:
Primary
- Determine host-related risk factors for developing symptomatic methemoglobinemia in
patients with pediatric hematologic malignancies or aplastic anemia who received
dapsone prophylaxis for pneumocystis carinii.
- Determine whether a deficiency in cytochrome b5 reductase is a risk factor for
symptomatic methemoglobinemia in a subset of these patients.
Secondary
- Collect a genomic DNA specimen from a subset of patients for whom enzyme testing is
being conducted to store for future analyses of variations in the genes responsible for
cytochrome b5 reductase.
OUTLINE: Patients' medical records are reviewed for possible risk factors (e.g., age, sex,
and body mass index) for developing symptomatic methemoglobinemia.
A subset of patients undergo blood sample collection for analysis of cytochrome b5 reductase
levels. DNA samples are also collected from these patients for future genetic polymorphism
studies.
Observational
N/A
Age, sex, and body mass index as host-related risk factors for developing symptomatic methemoglobinemia
No
Adam J. Esbenshade, MD
Principal Investigator
Vanderbilt-Ingram Cancer Center
United States: Federal Government
CDR0000651820
NCT00960050
June 2009
Name | Location |
---|---|
Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |